GlaxoSmithKline: Reorganizing Drug Discovery (A)

Below are the available bulk discount rates for each individual item when you purchase a certain amount

Register as a Premium Educator at hbsp.harvard.edu, plan a course, and save your students up to 50% with your academic discount.

Publication Date:
May 17, 2005

Industry:
Pharmaceuticals

Source:
Harvard Business School

Describes the reorganization of drug discovery at GlaxoSmithKline (GSK) following the formation of GSK from the merger of Glaxo Wellcome and SmithKline Beecham. This reorganization placed nearly 2,000 research scientists into six centers of excellence in drug discovery (CEDD). Each CEDD focused on a small set of therapeutic areas and possessed decision rights over the progression of pharmaceutical compounds through the early stages of development. Describes the proposed structure for the CEDDs and their relationship to remaining centralized departments within GSK’s R&D organization. Addresses issues about the benefits of focus vs. diversification in R&D, the role of decentralized vs. coordinated decision making, and the importance of alignment between the structural and infrastructural (e.g., performance incentives) aspects of an operating model. Using the empirical context of mergers in the pharmaceutical industry, the case allows students to build broader insights about the interaction between organizational form and operating performance.

Copyright © 2020 Harvard Business School Publishing. All rights reserved. Harvard Business Publishing is an affiliate of Harvard Business School.

GlaxoSmithKline: Reorganizing Drug Discovery (A)

Research & References of GlaxoSmithKline: Reorganizing Drug Discovery (A)|A&C Accounting And Tax Services
Source

Leave a Reply